Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 24:13:74.
doi: 10.1186/s12951-015-0136-y.

Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes

Garima Sharma  1   2 , Ashish Ranjan Sharma  3 , Ju-Suk Nam  4 , George Priya C Doss  5 , Sang-Soo Lee  6 , Chiranjib Chakraborty  7   8
Affiliations
Review

Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes

Garima Sharma et al. J Nanobiotechnology. .

Abstract

Diabetic cases have increased rapidly in recent years throughout the world. Currently, for type-1 diabetes mellitus (T1DM), multiple daily insulin (MDI) injections is the most popular treatment throughout the world. At this juncture, researchers are trying to develop different insulin delivery systems, especially through oral and pulmonary route using nanocarrier based delivery system. This next generation efficient therapy for T1DM may help to improve the quality of life of diabetic patients who routinely employ insulin by the subcutaneous route. In this paper, we have depicted various next generation nanocarrier based insulin delivery systems such as chitosan-insulin nanoparticles, PLGA-insulin nanoparticles, dextran-insulin nanoparticles, polyalkylcyanoacrylated-insulin nanoparticles and solid lipid-insulin nanoparticles. Modulation of these insulin nanocarriers may lead to successful oral or pulmonary insulin nanoformulations in future clinical settings. Therefore, applications and limitations of these nanoparticles in delivering insulin to the targeted site have been thoroughly discussed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Major two routes of nanocarrier based insulin delivery
Fig. 2
Fig. 2
Different types of insulin loaded nanoparticle based delivery system
See this image and copyright information in PMC

References

    1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–321. doi: 10.1016/j.diabres.2011.10.029. - DOI - PubMed
    1. Chakraborty C, Roy SS, Hsu MJ, Agoramoorthy G. Landscape mapping of functional proteins in insulin signal transduction and insulin resistance: a network-based protein-protein interaction analysis. PLoS One. 2011;6(1):e16388. doi: 10.1371/journal.pone.0016388. - DOI - PMC - PubMed
    1. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55(1):65–85. ([pii]: S0168822701003655). - PubMed
    1. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358(9283):739–746. doi: 10.1016/S0140-6736(01)05842-1. - DOI - PubMed
    1. Bener A, Saleh NM, Al-Hamaq A. Prevalence of gestational diabetes and associated maternal and neonatal complications in a fast-developing community: global comparisons. Int J Womens Health. 2011;3:367–373. doi: 10.2147/IJWH.S26094. - DOI - PMC - PubMed

Publication types